Search Page

1

Cite

Share

IVSPlat 1.0: an integrated virtual screening platform with a molecular graphical interface.

Sun YX, Huang YX, Li FL, Wang HY, Fan C, Bao YL, Sun LG, Ma ZQ, Kong J, Li YX. Sun YX, et al. Chem Cent J. 2012 Jan 5;6(1):2. doi: 10.1186/1752-153X-6-2. Chem Cent J. 2012. PMID: 22222098 Free PMC article.

Cite

Share

2

Cite

Share

[New oral anticoagulant drugs].

Berkovits A, Aizman A, Zúñiga P, Pereira J, Mezzano D. Berkovits A, et al. Rev Med Chil. 2011 Oct;139(10):1347-55. Epub 2012 Jan 3. Rev Med Chil. 2011. PMID: 22286737 Free article. Review. Spanish.

Cite

Share

3

Cite

Share

Stroke prevention in atrial fibrillation: understanding the new oral anticoagulants dabigatran, rivaroxaban, and apixaban.

Ru San T, Chan MY, Wee Siong T, Kok Foo T, Kheng Siang N, Lee SH, Chi Keong C. Ru San T, et al. Thrombosis. 2012;2012:108983. doi: 10.1155/2012/108983. Epub 2012 Sep 10. Thrombosis. 2012. PMID: 22997573 Free PMC article.

Cite

Share

4

Cite

Share

Intravitreal thrombin activity is elevated in retinal vein occlusion.

Bertelmann T, Stief T, Sekundo W, Mennel S, Nguyen N, Koss MJ. Bertelmann T, et al. Blood Coagul Fibrinolysis. 2014 Oct;25(7):654-9. doi: 10.1097/MBC.0000000000000109. Blood Coagul Fibrinolysis. 2014. PMID: 24625582

Cite

Share

5

Cite

Share

Non-Vitamin K Antagonist Oral Anticoagulant Use in Patients With Atrial Fibrillation and Associated Intracranial Hemorrhage: A Focused Review.

Arbit B, Hsu JC. Arbit B, et al. Clin Cardiol. 2015 Nov;38(11):684-91. doi: 10.1002/clc.22434. Epub 2015 Jul 14. Clin Cardiol. 2015. PMID: 26173428 Free PMC article. Review.

Cite

Share

6

Cite

Share

Ten common questions (and their answers) about off-label drug use.

Wittich CM, Burkle CM, Lanier WL. Wittich CM, et al. Mayo Clin Proc. 2012 Oct;87(10):982-90. doi: 10.1016/j.mayocp.2012.04.017. Epub 2012 Aug 6. Mayo Clin Proc. 2012. PMID: 22877654 Free PMC article.

Cite

Share

7

Cite

Share

Comparative effectiveness of warfarin and new oral anticoagulants for the management of atrial fibrillation and venous thromboembolism: a systematic review.

Adam SS, McDuffie JR, Ortel TL, Williams JW Jr. Adam SS, et al. Ann Intern Med. 2012 Dec 4;157(11):796-807. doi: 10.7326/0003-4819-157-10-201211200-00532. Ann Intern Med. 2012. PMID: 22928173 Review.

Cite

Share

8

Cite

Share

[Series: Clinical study from Japan and its reflections RE-LY trial].

Hori M. Hori M. Nihon Naika Gakkai Zasshi. 2012 May 10;101(5):1432-9. doi: 10.2169/naika.101.1432. Nihon Naika Gakkai Zasshi. 2012. PMID: 22693869 Clinical Trial. Japanese. No abstract available.

Cite

Share

9

Cite

Share

The oral thrombin inhibitor dabigatran: strengths and weaknesses.

Schulman S, Majeed A. Schulman S, et al. Semin Thromb Hemost. 2012 Feb;38(1):7-15. doi: 10.1055/s-0031-1300946. Epub 2012 Feb 7. Semin Thromb Hemost. 2012. PMID: 22314598 Review.

Cite

Share